Contribute Try STAT+ Today

WASHINGTON — Seema Verma, President Trump’s nominee to lead the Centers for Medicare and Medicaid Services, found herself Thursday performing a familiar high-wire act on drug prices.

As Democrats pressed her on Trump’s support for drug-price negotiations under Medicare Part D during a Senate Finance Committee hearing, Verma didn’t let herself get pinned down.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
  • Facts:
    1) 95% of all drugs are generic, and competition has already forced their prices down as far as they can go.
    2) The remainder of the drugs are either a) patent protected, and hence not subject to competition, or b) “rogue drugs” (Shkreli), where the drugs are single sourced, prices raised astronomically, and there is no competitive alternative.

    Obviously competition is NOT the answer, but incompetence has not seemed much of an impediment to Trump getting most of his picks through Congress so far.

Comments are closed.